Liver Cancer pp 303-310 | Cite as

Postoperative Interferon Alpha Treatment of Patients with Hepatocellular Carcinoma: Expression of p48 Using Tissue Microarray

  • Hui-Chuan Sun
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 5)

Hepatocellular carcinoma (HCC) is a major health problem in China and the third most common cause of cancer death in the world (Parkin et al., 2005). Surgical resection can have a curative outcome, but > 50% of patients will have recurrence in the first 5 years after resection (Poon, 2007), and the recurrence usually results in death (Regimbeau et al., 2004). No standard postoperative adjuvant therapy has yet been established (Sun and Tang, 2003).

In a previous study, we demonstrated that interferon-α (IFN-α) delays tumor growth and inhibits metastasis in a nude mouse model (Wang et al., 2000). Further studies revealed that both antiangio-genesis and antiproliferative effects are involved in the antitumor effect in the HCC model (Wang et al., 2003; Wu et al., 2004, 2005). In addition to the direct antitumor effect, the antivirus effect may also be involved in the prevention of recurrence of HCC. Some reports have indicated that long-term IFN-α reduces the incidence of HCC in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (Lin et al., 2007; Y u et al., 2006).


Hepatocellular Carcinoma Tissue Microarray Lular Carcinoma Tissue Microarray Analysis HBeAg Positive Chronic Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Camp, R.L., Charette, L.A., and Rimm, D.L. 2000. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80: 1943–1949.PubMedCrossRefGoogle Scholar
  2. Clifford, J.L., Menter, D.G., Yang, X., Walch, E., Zou, C., Clayman, G.L., Schaefer, T.S., El-Naggar, A.K., Lotan, R., and Lippman, S.M. 2000. Expression of protein mediators of type I inter-feron signaling in human squamous cell carcinoma of the skin. Cancer Epidemiol. Biomarkers Prev. 9: 993–997.PubMedGoogle Scholar
  3. Ghislain, J.J., Wong, T., Nguyen, M., and Fish, E.N. 2001. The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes. J. Interferon Cytokine Res. 21: 379–388.PubMedCrossRefGoogle Scholar
  4. Hewitt, S.M. 2006. The application of tissue microarrays in the validation of microarray results. Meth. Enzymol. 410: 400–415.PubMedCrossRefGoogle Scholar
  5. Ikeda, K., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y., Suzuki, F., Tsubota, A., Chayama, K., Murashima, N., and Kumada, H. 2000. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor — a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32: 228–232.PubMedCrossRefGoogle Scholar
  6. Jonasch, E., and Haluska, F.G. 2001. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34–55.PubMedCrossRefGoogle Scholar
  7. Kononen, J., Bubendorf, L., Kallioniemi, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M.J., Sauter, G., and Kallioniemi, O.P. 1998. Tissue microarrays for high-through-put molecular profiling of tumor specimens. Nat. Med. 4: 844–847.PubMedCrossRefGoogle Scholar
  8. Kubo, S., Nishiguchi, S., Hirohashi, K., Tanaka, H., Shuto, T., Yamazaki, O., Shiomi, S., Tamori, A., Oka, H., Igawa, S., Kuroki, T., and Kinoshita, H. 2001. Effects of long-term postoperative inter-feron-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepa-tocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 134: 963–967.PubMedGoogle Scholar
  9. Kurokawa, Y., Matoba, R., Nagano, H., Sakon, M., Takemasa, I., Nakamori, S., Dono, K., Umeshita, K., Ueno, N., Ishii, S., Kato, K., and Monden, M. 2004. Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. Clin. Cancer Res. 10: 6029–6038.PubMedCrossRefGoogle Scholar
  10. Lin, S.M., Lin, C.J., Hsu, C.W., Tai, DI., Sheen, I.S., Lin, D.Y., and Liaw, Y.F. 2004. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100: 376–382.PubMedCrossRefGoogle Scholar
  11. Lin, S.M., Yu, M.L., Lee, C.M., Chien, R.N., Sheen, I.S., Chu, C.M., and Liaw, Y.F. 2007. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocel-lular carcinoma. J. Hepatol. 46: 45–52.PubMedCrossRefGoogle Scholar
  12. Lugli, A., Tornillo, L., Mirlacher, M., Bundi, M., Sauter, G., and Terracciano, L.M. 2004. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am. J. Clin. Pathol. 122: 721–727.PubMedCrossRefGoogle Scholar
  13. Matin, S.F., Rackley, R.R., Sadhukhan, P.C., Kim, M.S., Novick, A.C., and Bandyopadhyay, S.K. 2001. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 61: 2261–2266.PubMedGoogle Scholar
  14. Murphy, D., Detjen, K.M., Welzel, M., Wiedenmann, B., and Rosewicz, S. 2001. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33: 346–356.PubMedCrossRefGoogle Scholar
  15. Ota, H., Nagano, H., Sakon, M., Eguchi, H, Kondo, M., Yamamoto, T., Nakamura, M., Damdinsuren, B., Wada, H., Marubashi, S., Miyamoto, A., Dono, K., Umeshita, K., Nakamori, S., Wakasa, K., and Monden, M. 2005. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br. J. Cancer 93: 557–564.PubMedCrossRefGoogle Scholar
  16. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. 2005. Global cancer statistics. 2002. CA Cancer J. Clin. 55: 74–108.PubMedCrossRefGoogle Scholar
  17. Poon, R.T. 2007. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann. Surg. Oncol. 14: 541–547.PubMedCrossRefGoogle Scholar
  18. Regimbeau, J.M., Abdalla, E.K., Vauthey, J.N., Lauwers, G.Y., Durand, F., Nagorney, D.M., Ikai, I., Yamaoka, Y., and Belghiti, J. 2004. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J. Surg. Oncol. 85: 36–41.PubMedCrossRefGoogle Scholar
  19. Rubin, M.A., Dunn, R., Strawderman, M., and Pienta, K.J. 2002. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am. J. Surg. Pathol. 26: 312–319.PubMedCrossRefGoogle Scholar
  20. Sun, H.C., and Tang, Z.Y. 2003. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma — a literature review of randomized control trials. World J. Gastroenterol. 9: 635–640.PubMedGoogle Scholar
  21. Sun, H.C., Tang, Z.Y., Ma, Z.C., Qin, L.X., Wang, L., Ye, Q.H., Fan, J., Wu, Z.Q., and Zhou, X.D. 2005. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J. Cancer Res. Clin. Oncol. 131: 284–288.PubMedCrossRefGoogle Scholar
  22. Sun, H.C., Tang, Z.Y., Wang, L., Qin, L.X., Ma, Z.C., Ye, Q.H., Zhang, B.H., Qian, Y.B., Wu, Z.Q., Fan, J., Zhou, X.D., Zhou, J., Qiu, S.J., and Shen, Y.F. 2006. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J. Cancer Res. Clin. Oncol. 132: 458–465.PubMedCrossRefGoogle Scholar
  23. Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., and Kakizoe, T. 2000. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocel-lular carcinoma: a randomised trial. Lancet 356: 802–807.PubMedCrossRefGoogle Scholar
  24. Wang, L., Tang, Z.Y., Qin, L.X., Wu, X.F., Sun, H.C., Xue, Q., and Ye, S.L. 2000. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32: 43–48.PubMedCrossRefGoogle Scholar
  25. Wang, L., Wu, W.Z., Sun, H.C., Wu, X.F., Qin, L.X., Liu, Y.K., Liu, K.D., and Tang, Z.Y. 2003. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 7: 587–594.PubMedCrossRefGoogle Scholar
  26. Wu, W.Z., Sun, H.C., Gao, Y.Q., Li, Y., Wang, L., Zhou, K., Liu, K.D., Iliakis, G., and Tang, Z.Y. 2004. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 67: 428–440.PubMedCrossRefGoogle Scholar
  27. Wu, W.Z., Sun, H.C., Shen, Y.F., Chen, J., Wang, L., Tang, Z.Y., Iliakis, G., and Liu, K.D. 2005. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J. Cancer Res. Clin. Oncol. 131: 169–178.PubMedCrossRefGoogle Scholar
  28. Yan, P., and Yan, L.N. 2003. Staging of hepatocel-lular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2: 491–495.PubMedGoogle Scholar
  29. Yu, M.L., Lin, S.M., Chuang, W.L., Dai, C.Y., Wang, J.H., Lu, S.N., Sheen, I.S., Chang, W.Y., Lee, C.M., and Liaw, Y.F. 2006. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 11: 985–994.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  • Hui-Chuan Sun
    • 1
  1. 1.Liver Cancer Institute and Zhongshan HospitalFudan UniversityShanghaiChina

Personalised recommendations